MedTrace Logo

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

NCT03186755 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-10-26

No results posted yet for this study

Summary

This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% \& Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergic conjunctivitis in the pediatric population. Half of participants will receive Hylo-Dual, while the other half will receive Olopatadine treatment for 2 months.

Conditions

  • Conjunctivitis, Allergic
  • Conjunctivitis, Vernal

Interventions

DRUG

Hyaluronic acid 0.05% & Ectoine 2.0%

Treatment of 1 drop three times a day in both eyes for 8 weeks

DRUG

Olopatadine hydrochloride ophthalmic solution 0.1%

Treatment of 1 drop two times a day in both eyes for 8 weeks

Sponsors & Collaborators

  • Université de Montréal

    collaborator OTHER

  • Michael Marchand, MD

    lead OTHER

Principal Investigators

  • Emilie Goodyear, MD · St. Justine's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-11
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03186755 on ClinicalTrials.gov